

LW  
copy

## CHECKLIST FOR MEETING RE PLASMA RISK ASSESSMENT

BETWEEN PETER GARWOOD/LORNA WILLIAMSON, NBS AND  
CHARLES LISTER/ANDRE HARE, DEPARTMENT OF HEALTH

15<sup>TH</sup> NOVEMBER 2000

1. Risk assessment models – medical/scientific and operational
2. Areas of uncertainty – vCJD risk/links with advice from SEAC
- ③ Availability of N American plasma
4. Would imported plasma, particularly from N America, require to be subjected to routine virus inactivation?
5. Some users are uncomfortable with the 'mixed economy', and are looking for central guidance as to which patients should be prescribed the virus-inactivated product. — *questionnaires*
6. If in the short-term we take steps to improve UK plasma further eg by steps to reduce transfusion-related acute lung injury (TRALI), then would this extra safety step have to be applied to any imported plasma?
7. How are financial considerations best handled?